Berlin, Germany, July 21, 2021 – The European Commission has granted marketing authorization in the European Union (EU) for vericiguat under the brand name Verquvo™. Verquvo (2.5 mg, 5 mg, and 10 mg), a soluble guanylate cyclase (sGC) stimulator, is indicated for symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy. It works differently to existing heart failure treatments, providing a specific approach to managing chronic heart failure patients following a decompensation event, also known as a worsening event.

Pre: USFDA approves KIT inhibitor Ayvakit (Avatinib)

Next: Novartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis